The premier interdisciplinary rehabilitation solution since 2003! Brainworks focuses in client-centred rehabilitation services for individuals who have been seriously injured in motor vehicle collisions, and their families. Brainworks offers innovative treatment programs to individuals with brain injury, chronic pain, depression & sleep disturbances. We provide direct rehabilitation services north of Toronto to north of Sudbury, with consultation, education & eRehabilitation service capabilities throughout Ontario.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MEDICAL

HEALTHPARTNERS, HELIX PARTNER TO CREATE DNA TESTING PROGRAM THAT HELPS FAMILIES BETTER UNDERSTAND THEIR GENETIC HEALTH

Helix | March 09, 2022

news image

HealthPartners and leading genomics company, Helix, are launching myGenetics, a population genomics program that will provide important health information to families across Minnesota and surrounding states. The myGenetics program hopes to enroll more than 100,000 participants over four years. Genomic data generated will be integrated with patient health records and shared during their personal clinical care. Through the partnership, HealthPartners will be able to identify risk ea...

Read More

CELL AND GENE THERAPY

NEUROPHTH AND AAVNERGENE ANNOUNCES STRATEGIC AAV CAPSIDS PARTNERSHIP FOR NEXT-GENERATION OPHTHALMIC GENE THERAPY

Neurophth | January 19, 2021

news image

Neurophth Therapeutics, Inc., a subsidiary of Wuhan Neurophth Biotechnology Ltd. gene therapy organization, and AAVnerGene Inc., a practicing AAV innovation organization, reports a strategic partnership to provide Neurophth with overall rights to commonly choose adeno-associated virus (AAV) capsids for the next generation ophthalmic gene therapy. AAVnerGene's Tissue-specific, Highly-transductive and Expressive New AAVs (ATHENA) screening stage can productively choose the best ...

Read More

HERON THERAPEUTICS TO INITIATE PHASE 2 CLINICAL STUDY OF CINVANTI® FOR COVID-19 TREATMENT

PR Newswire | July 17, 2020

news image

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the initiation of the GUARDS-1 Study, a Phase 2 clinical study evaluating CINVANTI (aprepitant) injectable emulsion in early hospitalized patients with Coronavirus Disease 2019 (COVID-19). The study initiation follows clearance from the U.S. Food and Drug Admin...

Read More

RESEARCH

ABVERIS ANNOUNCES MULTI-TARGET, MULTI-YEAR THERAPEUTIC ANTIBODY DISCOVERY COLLABORATION WITH PROMETHEUS BIOSCIENCES

Abveris, Biosciences | November 12, 2021

news image

Abveris, a leader in antibody drug discovery announced that Prometheus Biosciences and Abveris have entered a multi-year collaboration to develop therapeutic antibodies against multiple targets. The partnership will expand Abveris's role in supporting the rapid development of the Prometheus Biosciences portfolio. The results of the collaboration will bring promising new therapeutics to patients suffering from a variety of immune-mediated diseases. Under this partnership agreem...

Read More
news image

MEDICAL

HEALTHPARTNERS, HELIX PARTNER TO CREATE DNA TESTING PROGRAM THAT HELPS FAMILIES BETTER UNDERSTAND THEIR GENETIC HEALTH

Helix | March 09, 2022

HealthPartners and leading genomics company, Helix, are launching myGenetics, a population genomics program that will provide important health information to families across Minnesota and surrounding states. The myGenetics program hopes to enroll more than 100,000 participants over four years. Genomic data generated will be integrated with patient health records and shared during their personal clinical care. Through the partnership, HealthPartners will be able to identify risk ea...

Read More
news image

CELL AND GENE THERAPY

NEUROPHTH AND AAVNERGENE ANNOUNCES STRATEGIC AAV CAPSIDS PARTNERSHIP FOR NEXT-GENERATION OPHTHALMIC GENE THERAPY

Neurophth | January 19, 2021

Neurophth Therapeutics, Inc., a subsidiary of Wuhan Neurophth Biotechnology Ltd. gene therapy organization, and AAVnerGene Inc., a practicing AAV innovation organization, reports a strategic partnership to provide Neurophth with overall rights to commonly choose adeno-associated virus (AAV) capsids for the next generation ophthalmic gene therapy. AAVnerGene's Tissue-specific, Highly-transductive and Expressive New AAVs (ATHENA) screening stage can productively choose the best ...

Read More
news image

HERON THERAPEUTICS TO INITIATE PHASE 2 CLINICAL STUDY OF CINVANTI® FOR COVID-19 TREATMENT

PR Newswire | July 17, 2020

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced the initiation of the GUARDS-1 Study, a Phase 2 clinical study evaluating CINVANTI (aprepitant) injectable emulsion in early hospitalized patients with Coronavirus Disease 2019 (COVID-19). The study initiation follows clearance from the U.S. Food and Drug Admin...

Read More
news image

RESEARCH

ABVERIS ANNOUNCES MULTI-TARGET, MULTI-YEAR THERAPEUTIC ANTIBODY DISCOVERY COLLABORATION WITH PROMETHEUS BIOSCIENCES

Abveris, Biosciences | November 12, 2021

Abveris, a leader in antibody drug discovery announced that Prometheus Biosciences and Abveris have entered a multi-year collaboration to develop therapeutic antibodies against multiple targets. The partnership will expand Abveris's role in supporting the rapid development of the Prometheus Biosciences portfolio. The results of the collaboration will bring promising new therapeutics to patients suffering from a variety of immune-mediated diseases. Under this partnership agreem...

Read More